On January 2, 2025, Kathryn Guarini, an insider at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Guarini's direct ownership of Regeneron Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions or disposals mentioned in the filing.

On January 2, 2025, Kathryn Guarini, an insider at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Guarini's direct ownership of Regeneron Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions or disposals mentioned in the filing.